News | March 14, 2022
Applications for PLI in bulk drugs extended till March 31st 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
The product will be manufactured at Lupin’s facility in Goa, India
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Price was the key driver for the period
Subscribe To Our Newsletter & Stay Updated
